Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06806995 · ClinicalTrials.gov registry record · Phase 1
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
A Phase 1 study of PHA1A, sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06806995 is a Phase 1 study of PHA1A that has completed, run by Wockhardt. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06806995, a Phase 1 study of PHA1A, has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, Single-Center, Open-Label study evaluating the safety and pharmacokinetics of single doses of ZID-FEP and metronidazole alone or in combination utilizing a 3-period, crossover study design. Thirty eligible male and female healthy adult subjects will participate in the study and receive single doses of (1) ZID-FEP 3g IV (ZID 1 g plus FEP 2 g) administered over 1 hour (h); (2) metronidazole 0.5 g IV alone administered over 1 h; and (3) metronidazole 0.5 g IV over 1 h, followed by ZID-FEP 3g IV over 1 h over 3 treatment periods separated by a 48 h washout period.
Conditions Studied
Interventions
- DRUG Metronidazole
- DRUG Zidebactam-Cefepime
- DRUG FEP-ZID
Study Locations (1)
Florida
- Advanced Pharma CR, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06806995
The ClinicalTrials.gov registry entry for NCT06806995 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wockhardt, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PHA1A appearing as the primary indexed condition, and to 3 interventions - of which Metronidazole is the first listed.
NCT06806995 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06806995 about?
NCT06806995 is a clinical study titled "A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.". This is a Phase I, Single-Center, Open-Label study evaluating the safety and pharmacokinetics of single doses of ZID-FEP and metronidazole alone or in combination utilizing a 3-period, crossover study design. Thirty eligible male and female healthy adult subjects will participate in the study and re...
What is the current status of trial NCT06806995?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-01-21. Estimated completion is 2025-02-17.
What conditions does trial NCT06806995 study?
This clinical trial studies the following conditions: PHA1A.
What interventions are being tested in trial NCT06806995?
The interventions under investigation include: Metronidazole (DRUG), Zidebactam-Cefepime (DRUG), FEP-ZID (DRUG).
Who is sponsoring clinical trial NCT06806995?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06806995 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PHA1A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.